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SERCA/PLB ratioIncreased cardiovascular risk after mercury exposure has been described but cardiac effects resulting from
controlled chronic treatment are not yet well explored. We analyzed the effects of chronic exposure to low
mercury concentrations on hemodynamic and ventricular function of isolated hearts.
Wistar rats were treated with HgCl2 (1st dose 4.6 μg/kg, subsequent dose 0.07 μg/kg/day, im, 30 days) or
vehicle. Mercury treatment did not affect blood pressure (BP) nor produced cardiac hypertrophy or changes of
myocyte morphometry and collagen content. This treatment: 1) in vivo increased left ventricle end diastolic
pressure (LVEDP) without changing left ventricular systolic pressure (LVSP) and heart rate; 2) in isolated
hearts reduced LV isovolumic systolic pressure and time derivatives, and β-adrenergic response; 3) increased
myosin ATPase activity; 4) reduced Na+-K+ ATPase (NKA) activity; 5) reduced protein expression of SERCA
and phosphorylated phospholamban on serine 16 while phospholamban expression increased; as a
consequence SERCA/phospholamban ratio reduced; 6) reduced sodium/calcium exchanger (NCX) protein
expression and α-1 isoform of NKA, whereas α-2 isoform of NKA did not change.
Chronic exposure for 30 days to low concentrations of mercury does not change BP, heart rate or LVSP but
produces small but signiﬁcant increase of LVEDP. However, in isolated hearts mercury treatment promoted
contractility dysfunction as a result of the decreased NKA activity, reduction of NCX and SERCA and increased
PLB protein expression. These ﬁndings offer further evidence that mercury chronic exposure, even at small
concentrations, is an environmental risk factor affecting heart function.al Sciences, Federal University
, 29040-091 Vitoria, ES, Brazil.
o).
vier OA license.© 2011 Elsevier Inc. Open access under the Elsevier OA license.Introduction
Adverse effects of mercury were mainly recognized in the 1970s
due to the disasters of Minamata Bay (Eto, 2000) and Iraq (Bakir et al.,
1973). Increased cardiovascular risk after mercury exposure has been
reported, and both acute and chronic mercury exposure produces
several toxic effects on the cardiovascular system.
Acute mercury administration reduces arterial blood pressure
(Rhee and Choi, 1989; Rossoni et al., 1999) and myocardial
contractility (Oliveira et al., 1994). Acute HgCl2 (5 mg/Kg) also
produces cardiac systolic and diastolic failure, and pulmonary
hypertension in vivo (Rossoni et al., 1999). In left ventricular papillarymuscles, 0.5 and 1 μM HgCl2 increase force development (Oliveira
et al., 1994; Assis et al., 2003) probably resulting from the inhibition of
sarcolemmal Na+,K+-ATPase (NKA) (Anner et al., 1992). At higher
concentrations, mercury produces a negative inotropism as a
consequence of calcium overload by reducing sarcoplasmic reticulum
Ca2+-ATPase activity (Hechtenberg and Beyersmann, 1991). The
metal also reduces tetanic tension development and myosin ATPase
activity (Vassallo et al., 1999; Moreira et al., 2003) at these
concentrations. In Langendorff-perfused hearts, perfusion with high
concentrations of mercury also reduces cardiac contractility, thereby
decreasing isovolumic pressure development (Rhee and Choi, 1989,
Massaroni et al., 1995).
Attention has recently been focused on the cardiovascular toxic
effects of chronic mercury exposure and its association with
hypertension, carotid atherosclerosis, myocardial infarction and
coronary heart disease (Salonen et al., 2000; Virtanen et al., 2005;
Houston, 2007). Different forms of mercury, such as HgCl2 andmethyl
mercury, have different actions and adverse outcomes when acutely
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proximate toxic agent is most likely inorganic mercury (Rooney,
2007). Moreover, studies reporting mercury effects resulting from
chronic exposition are still scarce and the underlying mechanisms are
not yet well explored.
In order to adequately control amounts of mercury absorption, we
developed an experimental model for controlled chronic exposure to
low concentrations of HgCl2; such a model describes an endothelial
dysfunction in aorta and mesenteric resistance arteries due to
decreased NO bioavailability by increased NADPH oxidase-derived
O2- (Wiggers et al., 2008). We then investigated whether the effects of
chronic exposure to low concentrations of mercury also affects cardiac
contractility by evaluating effects on arterial and ventricular pres-
sures, isolated heart, NKA and myosin ATPase activities, expression of
calcium handling proteins and changes in myocyte morphometry.
Findings provide further evidence that chronic exposure to low doses
of mercury, even at concentrations considered to be safe, is an
environmental risk factor for heart function and cardiovascular
disease.
Material and methods
Animals. Three-month-old male Wistar rats were obtained from the
Animal Quarters of the Federal University of Espirito Santo. Rats were
housed during treatment at a constant room temperature, humidity,
and light cycle (12:12-h light-dark)with free access to tapwater and fed
standard chow ad libitum. Rats were divided into two groups: control
(vehicle–saline solution, im) and those treated with mercury chloride
for 30 days (1st dose 4.6 μg/kg, subsequent dose 0.07 μg/kg/day, i.m to
cover daily loss). Our group described that this treatment led to blood
levels of ~8 ng/mL (Wiggers et al., 2008). All experiments were
conducted in compliance with the guidelines for biomedical research
as stated by the Brazilian Societies of Experimental Biology, were in
accordance with the National Institute of Health Guidelines for the Care
and Use of Laboratory Animals and were approved by local ethics
committee (CEUA-EMESCAM 003/2007, 007/2007).
Arterial blood pressure, ventricular pressure and heart rate measurements.
At the end of treatment, rats (N=22) were anesthetized with urethane
(1.2 g/kg, Sigma (St Louis, MO, USA), and a polyethylene catheter
(PE50) ﬁlled with heparinized saline (50 U/ml)was introduced into the
carotid artery to measure arterial systolic blood pressure (SBP) and
diastolic blood pressure (DBP). The carotid artery catheter was
introduced into the left ventricle to measure systolic pressure (LVSP)
and its positive and negative time derivatives (dP/dt+LV and dP/dt−
LV, respectively), as well as left ventricular end diastolic pressure
(LVEDP). Recordings were performed over a 30-min period with a
pressure transducer (TSD104A), and with an interface and data
collection software (MP100A, BIOPAC System, Inc., Santa Barbara, CA,
USA). Heart rate (HR) was determined from intra-beat intervals.
Isolated heart perfusion. After treatment, rats (N=14) were anesthe-
tized with urethane (1.2 g/kg), treated with heparin (500 UI, i.p.) and
euthanized by exsanguination; the heart was excised after 10 min and
mounted in an isolated organ chamber and perfused according to the
Langendorff technique at constant ﬂow (10 mL/min) with Krebs–
Henseleit bicarbonate buffered solution containing (in mM): 120
NaCl, 5.4 KCl, 1.25 CaCl2, 2.5 MgSO4, 1.2 Na2SO4, 2.0 NaH2PO4, 20
NaHCO3, and 11 glucose (salts usedwere of analytical grade; Sigma, St
Louis, MO, USA and Merk, Darmstat, Germany). This solution was
ﬁltered and continuously bubbled with 95% O2 and 5% CO2 (pH=7.4)
and kept between 34 and 35 °C. After mounting, the left atrium was
opened and a soft distensible balloon mounted at the tip of a rigid
plastic tube was inserted into the left ventricular cavity through the
atrioventricular valve. To avoid liquid accumulation in the ventricular
cavity, the ventricle was perforated with a puncture needle. Theballoon was connected, via a Y piece, to a pressure transducer (TSD
104A) and to a syringe so that the diastolic pressure of the left
ventricle could be adjusted to predetermined values by injecting
water into the balloon. The resulting pressure was registered. The
hearts were driven with isolated suprathreshold rectangular pulses
(5 ms duration) at a constant rate (3.3 Hz) through a pair of Ag/AgCl
electrodes attached to the upper region of the right ventricle.
Mechanical activity was investigated by measuring developed left
ventricular isovolumic systolic pressure (LVISP). To evaluate contrac-
tility the rate of rise of LVISP (dP/dt) was used because it is highly
sensitive to changes in contractility (Gleason and Braunwald, 1962).
These parameters were measured with a pressure transducer
connected to an ampliﬁer (MP 100 Biopac Systems: Inc.; CA) and
recorded with a data acquisition system (BIOPAC MP100WSW,
including a software Acqknowledge III, Goleta, CA). The isovolumic
pressure derivative (dP/dt) was gotten ofﬂine by the same software
(digital ﬁlter Blackman−61 dB, 25 KHz of cut frequency and sample
rate of 1000/s). All measurements began 30 min after mounting to
allow the beating preparation to adapt to the in vitro conditions. The
coronary perfusion pressure (CPP) was continuously registered by
connecting a pressure transducer (TDS 104A) to the inﬂow of the
aortic pressure tube. Since coronary ﬂow was kept constant (10 mL/
min), changes of the CPP were dependent on changes of coronary
resistance.
Protocols were performed beginning with a constant diastolic
pressure of 5 mm Hg by adjusting the volume of the balloon.
Ventricular function curves were obtained by measuring the left
ventricular isovolumic systolic pressure (LVISP) developed while
diastolic pressure was increased from 0 to 30 mm Hg in steps of
5 mm Hg. Balloon volume was kept constant during experiments
involving other protocols; this permitted changes in diastolic and
systolic pressures to be measured. Initially, recordings were taken
under control conditions in both groups. In order to analyze
inotropic response, a single dose of isoproterenol (Sigma, St Louis,
MO, USA) in bolus (100 μl, 10 μM) was administered to evaluate β-
adrenoceptor response.
Assay of cardiac myosin ATPase activity. Some animals were killed at
the end of hemodynamic measurements. The hearts were rapidly
frozen in liquid nitrogen and kept at −80 °C until the day of
analysis. Brieﬂy, as previously reported (Moreira et al., 2003),
myosin was prepared from minced and homogenized left ventricles
extracted with KCl-phosphate buffer (0.3 M KCl and 0.2 M phos-
phate buffer [pH 6.5](Klotz et al., 1975)). Myosin ATPase activity
was assayed according to previous reports (Klotz et al., 1975;
Cappelli et al., 1989) by measuring inorganic phosphate (Pi)
liberation from 1 mM ATP in the presence of 50 mM HEPES (pH
7), 0.6 M KCl, 5 mM CaCl2, or 10 mM ethylene glycol-bis (β-amino
ethyl ether)-N,N,N′,N′-tetra acetic acid (EGTA) in a ﬁnal volume of
200 μL. Samples were assayed in duplicate or triplicate and
corrected for non-enzymatic hydrolysis by using controls assayed
in the same conditions, except that the protein sample was added
after the interruption of the reaction by using 200 μL of 10%
trichloroacetic acid. The reaction was initiated by addition of the
protein sample to avoid the inactivation at 30 °C caused by a lack of
substrate. The enzyme activity was calculated as the difference
between activities observed in the presence of Ca2+ and that in the
presence of 10 mM EGTA. Pi was determined by the method of Chan
et al. (1986) (Chan et al., 1986). The speciﬁc activity was reported as
nmol Pi released per min per mg of protein. Protein was measured
by the Coomassie blue method using bovine serum albumin as a
standard (Bradford, 1976).
Na+-K+ ATPase activity assay. The enzymatic material was extrac-
ted as described by Velema and Zaagsma (1981) with the following
modiﬁcations: ventricular tissue was homogenized in a solution
Table 1
Body weight and ventricular weights from Control and HgCl2 treated rats.
Control N HgCl2 N
BW initial (g) 251±4 12 251±5 12
BW ﬁnal (g) 364±4 12 365±8 12
LV (mg) 886±42 12 904±47 12
LV/BW (mg/g) 2.3±0.1 12 2.4±0.1 12
RV (mg) 229±11 12 227±8 12
RV/BW (mg/g) 0.6±0.02 12 0.6±0.03 12
Initial and ﬁnal body weight (BW); Left (LV) and right (RV) ventricular weight; LV/BW
and RV/BWweight ratios from Control and HgCl2-treated rats. Results represent mean±
SEM. N-Number of animals used. *pb0.05. Student's t test.
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activity was assayed by measuring Pi liberation from 3 mM ATP in the
presence of NaCl 125 mM, MgCl2 3 mM, KCl 20 mM and Tris–HCl
50 mM (pH 7.5). The enzyme was preincubated for 5 min at 37 °C and
the reaction was initiated by adding the ATP. Incubation times and
protein concentration were chosen in order to ensure the linearity of
the reaction. The reaction was stopped by the addition of 200 μL of
10% trichloroacetic acid. Controls with addition of the enzyme
preparation after addition of trichloroacetic acid were used to correct
for nonenzymatic hydrolysis of the substrate. All samples were in
duplicate. The speciﬁc activity was reported as nmol Pi released per
min per mg of protein unless otherwise stated. The speciﬁc activity of
enzyme was determined in the presence and absence of 5 mM of
ouabain.
Western blot analysis. After Langendorff experiments, hearts were
homogenized and proteins [50 μg for PLB, PLB- phospho-Ser16 and
100 μg for SERCA, NCX, α-1, α-2] were separated by 7.5% (SERCA,
NCX,α-1 and α-2), 15% (PLB) SDS-PAGE. Proteins were transferred to
nitrocellulose membranes and were incubated with mouse monoclo-
nal antibodies for SERCA (1:500, Afﬁnity BioReagents, CO, USA), NCX
(1:200, Abcam Cambridge, MA, USA), PLB (2 μg/mL, Afﬁnity Bio-
Reagents, CO, USA), α-1 (1:1000, Upstate, Billerica, MA) or rabbit
polyclonal antibodies for PLB phospho-Ser16 (1:5000, Badrilla, Leeds,
UK) and α-2 (1:1000, Upstate, Billerica, MA). After washing,
membranes were incubated with anti-mouse or anti-rabbit (1:5000,
StressGen, Victoria, Canada) immunoglobulin antibody conjugated to
horseradish peroxidase. After thorough washing, immunocomplexes
were detected using an enhanced horseradish peroxidase/luminal
chemiluminescence system (ECL Plus, Amersham International, Little
Chalfont, UK) and ﬁlm (Hyperﬁlm ECL International). Signals on the
immunoblot were quantiﬁed with the National Institutes of Health
Image V1.56 computer program. The same membrane was used to
determine GAPDH expression using a mouse monoclonal antibody
(1:5000, Abcam Cambridge, MA, USA).
Morphometric analysis. In the present study, two different quantiﬁ-
cations were considered in order to analyze putative actions of
mercury treatment on cardiac structure. Firstly, a determination was
made as to whether treatment couldmodify the size or morphology of
myocyte cell bodies. Secondly, it was determined if themeasurements
could detect a variation in collagen content.
Cardiomyocyte cell body quantiﬁcation. Histologic sections of ventric-
ular tissue of 4-μm thickness were stained with Masson's trichrome.
Three sections for each animal were analyzed using a high resolution
monochromatic photocamera CCD (SonyXC-75CE) attached to a
photomicroscope (LeicaDMRB). The morphometric analyses were
performedwith an Image System Analysis (Leica Q500MC) with 8 bits
of images in gray gradation (256 levels of gray: 0 representing black as
blank and 255 colors). The binary edition was used to remove artifacts
that did not correspond to cardiomyocyte (cell body) stained area.
Cardiomyocyte (60–80 per animal) analyses were performed with
40× lenses in which the cell nuclei were clearly observed. The same
illumination conditions were used for all measurements. Calibration
of the system was carried out using a stage micrometer (Leitz) that
allowed computation of the object area in units of μm2.
Cardiac collagen quantiﬁcation. Regarding the collagen content eval-
uation we used Picrius Sirius red staining. This technique is widely
used for measuring collagen content in different tissues. Tissue
samples were dehydrated, embedded in parafﬁn and cut in sections of
(4 μm) thickness. These sections were stained with 0.5% Sirius Red
F3BA (Aldrich Chemical Company). The quantiﬁcation of collagen in
left ventricle was performed using an image analysis system from
LEICA (LEICA 500YW, Cambridge, UK) and expressed as percent oftissue area. A single researcher unaware of the experimental groups
performed the analysis.
Data analysis and statistics. Results are reported as means±SEM.
Differences were analyzed using Student's t-test or two-way ANOVA
followed by a Tukey test. p≤0.05 was considered signiﬁcant. For
protein expression, data are expressed as the ratio between signals on
the immunoblot corresponding to the studied protein and GAPDH.
Results
In rats exposed to 30-day HgCl2 treatment no differences in body
weight between groups were observed either before or after
treatment. Left and right ventricles weight normalized by body
weight also showed no differences (Table 1).
In order to investigate cardiac effects, Langendorff-perfused hearts
from both controls and from 30-day exposed rats were used. Fig. 1
shows that the LVISP was reduced in the mercury-treated group with
diastolic pressure ﬁxed at 5 mm Hg. Reduction was also observed for
positive and negative dP/dt, while coronary perfusion pressure did
not change. When performing ventricular function curves, LVISP was
reduced in the mercury-treated group for all diastolic pressure values
(Fig. 2A). Similar behavior was obtained with positive and negative
dP/dt (Figs. 2B–C), but diastolic pressure increments did not change
the coronary perfusion pressure (data not shown).
Isoproterenol was used in order to test if HgCl2 treatment could
alter the myocardial response to inotropic interventions. Isoprotere-
nol administration (100 μL, 10 μM, in bolus) increased LVISP and
positive and negative dP/dt in both groups. However, the increase in
LVISP and positive dP/dt showed a percentage reduction in the
mercury-treated group suggesting a reduction in the β-adrenergic
inotropic action (Fig. 3). During this inotropic intervention no changes
in coronary perfusion pressure were observed.
In order to investigate the underlying mechanisms that could
explain those mechanical effects on hearts frommercury-treated rats,
NKA andmyosin ATPase activities weremeasured. Myocardial myosin
ATPase activity was increased (Ct: 257.7±11.7 vs HgCl2: 301.5±
9,3 nmol Pi/min/mg, Pb0.05) while NKA activity was reduced (Ct:
59.8±4.5 vs HgCl2: 35.3±8.6 nmol Pi/min/mg, Pb0.05) in the
mercury-treated group. Protein expressions of NCX, α1 and α2
subunits of NKA, SERCA, phospholamban and its phosphorilated
fraction were measured (Figs. 4 and 5) in order to evaluate calcium
handling mechanisms. After 30-day mercury treatment reduces
expression of alfa-1 NKA subunit and NCX expression, but expression
of alfa-2 NKA subunit did not change. Moreover, after exposure to low
doses of mercury, SERCA expression and phosphorilated phospho-
lamban were reduced while phospholamban expression was in-
creased. These changes led to a reduction in SERCA/PLB ratio,
suggesting the reduction in calcium uptake by the sarcoplasmic
reticulum contributing to the calcium overload.
Since no changes in myocardial mass were found analyzing
ventricular weight we investigated myocardial morphology by analyz-
ing putative actions of mercury treatment on cell morphometry. No
Fig. 1. (A) LVISP— Left ventricle systolic isovolumetric pressure, (B) positive ﬁrst time
derivative (dP/dt +), (C) negative ﬁrst time derivative (dP/dt -) and (D) coronary
perfused pressure from Control (CT) and HgCl2-treated (HgCl2) rats under control
conditions in Langendorff apparatus. Results represent mean±SEM. Number of
animals used is indicated in parentheses. *pb0.05. Student's t test.
Fig. 3. β-adrenergic activation by isoproterenol (100 μL, 10 μM, in bolus) in Langendorff
apparatus on LVISP (A), dP/dt+(B), dP/dt – (C) and on CPP (D) from Control and
HgCl2-treated rats. Results represent mean±SEM. Number of animals used is indicated
in parentheses. *pb0.05. Student's t test.
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length and area of myocardial cells (results not shown). In addition, no
changes were observed in collagen fraction in left ventricle from the
mercury-treated group as compared with controls (5.1±0.8 vs 4.7±
0.6% of tissue area).
To investigate if such changes could produce hemodynamic effects,
we performed measurements of systolic, diastolic, mean arterial
pressure and heart rate in anesthetized rats. No differences were
observed between the two groups (Table 2). The measurement of
ventricular pressures, LVSP and time derivatives also did not change.
However, only LVEDP increased in the 30-day mercury-treated group.Fig. 2. (A) LVISP— Left ventricle systolic isovolumetric pressure, (B) positive ﬁrst time deriv
diastolic pressure (DP) from Control and HgCl2-treated rats. Results represent mean±SEMDiscussion
The main ﬁndings presented here show that 30-day treatment
with low mercury concentration produced a negative inotropic effect
in perfused hearts, although myosin ATPase activity increased. This
contractility reduction was explained by alterations in calcium-
handling mechanisms because of both diminished protein expression
of SERCA, NKA (α1 subunit) and NCX, and increased PLB expression
together with a reduced response to β-adrenergic stimulation. This
treatment did not change arterial or ventricular pressures, although it
produced a small but signiﬁcant increase of LVEDP in anesthetized
rats.ative (dP/dt +), (C) negative ﬁrst time derivative (dP/dt -) curves obtained at different
. *pb0.05. ANOVA two-way and Tukey test.
Fig. 4. Densitometric analysis of the Western blot for (A) NCX, (B) α-1 and (C) α-2
isoform of Na+-K+ ATPase from control and HgCl2-treated rats. Number of animals
used is indicated in parentheses. *pb0.05 by Student's t test. Representative blots are
also shown.
Fig. 5. Densitometric analysis of the Western blot for (A) SERCA (B) PLB (C) PLB-
phospho Ser16 and (D) SERCA/PLB ratio protein expression in hearts from control and
HgCl2-treated rats. Number of animals used is indicated in parentheses. *pb0.05 by
Student's t test. Representative blots are also shown.
Table 2
Hemodynamic parameters from untreated and HgCl2-treated rats.
Control N HgCl2 N
HR (bpm) 303±14 10 319±12 11
SBP (mm Hg) 103±6 10 110±5 11
DBP (mm Hg) 57±4 10 62±5 11
MBP (mm Hg) 77±6 10 75±5 11
LVSP (mm Hg) 110±9 8 119±7 10
LVEDP (mm Hg) 2.2±0.3 8 3.9±0.4⁎ 10
dP/dt+LV (mm Hg/s) 3972±740 8 4579±617 10
dP/dt−LV (mm Hg/s) 4827±547 8 4995±495 10
Changes in systolic (SAP), diastolic (DAP) and mean blood pressure(MBP), heart rate
(HR), left ventricle systolic pressure (LVSP), left ventricle end diastolic pressure
(LVEDP) and in positive (dP/dt +) and negative ﬁrst time derivatives (dP/dt -) from
Control and HgCl2-treated rats. Results represent mean±SEM. N- Number of animals
used. Student's t test.
⁎ pb0.05.
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cardiovascular diseases (Houston, 2007). The reference blood con-
centration of mercury recommended by the US Enviromental
Protection Agency's, below which exposure is considered to be
without adverse effect, is 5.8 ng/mL (National Academy of Sciences,
2000; Rice, 2005; Stern, 2005). In control populations, blood mercury
concentration was reported to be 2.73 ng/mL in adults in New York
City and 1 ng/mL in China. Mercury attains levels of 5.65 ng/mL
(McKelvey et al., 2007) in regular ﬁsh consumption, and in workers
that are regularly exposed attain levels between 7 and 10 ng/mL
(Gupta et al., 1996; Chen et al., 2005).
Professional exposure to mercury vapor and release of mercury
from removal of amalgam dental ﬁllings increases its blood (18 nM;
~5 ng/mL) and plasma (5 nM; ~1.5 ng/mL) concentration (Halbach,
1995; Björkman et al., 1997; Langworth et al., 1997; Sandborgh-
Englund et al., 1998). This form of the exposure is represented by
elemental mercury. Once absorved it can be oxidized into inorganic
mercury (Rooney, 2007; Björkman et al., 2007). Professional exposure
also produces central nervous system alteration (Langworth et al.,
1997) and tooth ﬁllings impair kidney function (Carmignani et al.,
1989).
Mercury exerts its effects by combining with SH groups (Clarkson,
1972) and these actions might be the manner by which the metal
exerts its effects on the cardiac myocytes (Halbach, 1989). However,
the fact that mercury can concentrate inside the cells suggests that the
metal might produce effects at even lower concentrations under
chronic exposure. We have previously reported that chronic exposure
to small concentrations do produce harmful vascular effects (Furieri
et al., 2011; Wiggers et al., 2008) but studies regarding cardiac
function with chronic exposure to low concentrations of the metal are
scarce.
Given that relatively high blood levels of mercury are more likely
to pose the metal as an environmental risk factor for cardiovas-
cular diseases, we recently developed a method for producing a
controlled chronic mercury administration that attains a blood con-
centration of 8 ng/mL (~29 nM). Using a similar exposure protocol,
and to avoid effects of humoral and neural factors that exist in
the blood, the perfused heart preparation was used. In these prepa-
rations a negative inotropic and lusitropic effect was observed in the
mercury-treated group. The underlying mechanisms that could
explain these ﬁndings are usually the reduction of NKA, NCX and
SERCA activities (Bers, 2006). Biochemical analyses performed here
showed that chronic mercury treatment reduces NKA activity, the
expression of alfa-1 NKA subunit and NCX expression. Results also
show reduction of SERCA expression, PLB increase and phosphorilated
PLB reduction, which might lead to less calcium uptake and release.
Such condition is known to reduce force development (Bers and
Despa, 2006).
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increased intracellular sodium concentration, which reduces NCX
activity, producing a calcium overload condition. In addition, the
reduction of SERCA expression and phosphorilated phospholamban,
while occurring an increase in phospholamban expression, reduced
the SERCA/PLB ratio. These changes suggest that calcium uptake by
the sarcoplasmic reticulum is reduced, which contributes to the
calcium overload. Consequently, the release of less calcium upon
activation reduces force development.
Taken together these ﬁndings explain the reduced mechanical
activity found in isolated hearts suggesting that mercury treatment
might produce calcium overload. Considering that for the isolated
perfused heart there is no protection by homeostatic mechanisms, the
perfused heart showed reduction of cardiac mechanical activity,
reinforcing the suggestion that this treatment begins to present signs
of Hg toxicity.
Although mercury treatment reduced pressure generation, coro-
nary perfusion pressure remained unchanged, even when isoproter-
enol was used. β-adrenergic activation should produce a
vasodilatation after pressure increment. However, we should empha-
size that the coronary ﬂow depends mainly on a metabolic control
(Gutterman and Cowley, 2006). Considering that both control and Hg-
treated hearts presented similar coronary perfusion pressure we
concluded that the coronary ﬂow used was sufﬁcient to maintain
myocardial metabolic demands.
Since signs of mercury toxicity were observed in vitro we
investigated mercury effects in anesthetized animals. Arterial and
ventricular pressures were measured. No changes were observed
compared to the non-treated rats. Similar results were found for
arterial systolic pressure measured in awake rats when using a tail
cuff technique (Wiggers et al., 2008). We should consider that the in
vitro assay is not a good model to reproduce what occurs in vivo. A
possible explanation for why in vitro LVISP was reduced in mercury-
treated perfused hearts is the increased myosin ATPase activity and a
putative rise in sympathetic tone that reduced the β-adrenergic
response to isoproterenol found in the isolated perfused heart.
However, the increment of LVEDP and reduction in dP/dt during
relaxation observed in mercury-treated rats indicate that there is some
damage to ventricular mechanisms. We observed a reduction of NKA
activity, NCX and SERCA expression and an increase in PLB expression.
These ﬁndings taken together explain the generation of a calcium
overload condition and LVEDP increase after mercury treatment. What
is more, SERCA activity reductions and PLB increases are usually
accompanied by increased LVEDP (Sjaastad et al., 2003), which is not
unlike what is observed in other conditions such as heart failure. This
negative inotropism and lusitropism in vivo were then blunted by the
increased myosin ATPase activity and a rise in sympathetic tone. It is
worth emphasizing that β-adrenergic activation regulates myosin
ATPase activity through cyclic adenosine monophosphate, which
explains this association (Winegrad et al., 1986).
Because LVW/BW and RVW/BWdid not change we also performed
morphometric analyses. After mercury treatment no changes were
observed for perimeter, length, width or area of myocytes. Regarding
the evaluation in collagen content in mercury-treated animals
compared with controls no changes were observed. Since 30 days
mercury treatment with low doses did not produce morphological
alterations our ﬁndings suggest that functional changes here
described are not consequence of morphological changes.
Potential limitations of the study. In the present study,weusedﬂuid-
ﬁlledmanometric systemas amethod for performing thehemodynamic
experiments. If we compared the present results with those performed
using microtip pressure transducers, we observed that the present
values obtained with polyethylene catheter are lower when compared
to those obtainedwith themicrotip catheter (Zimmer andMillar, 1998).
Results using the microtip catheter are commonly performed in
anesthetized rats, thereby reducing differences with the ﬂuid-ﬁlledcatheters. Because the use of anesthesia changes hemodynamic
parameters, we used the ﬂuid-ﬁlled manometric system to perform
the present experiments, keeping inmind both the catheter's resonance
effect and dumping which this manometric system produces. In any
case, as the sameﬂuid-ﬁlledmanometric systemwasused toperformall
experiments, we believe the present results to be acceptable.
In summary, results presentedherein suggest that controlled chronic
exposure to small concentrations of inorganic mercury, leading to
plasma levels similar to those found after continuous occupational
exposure, begins to affect heart function, eventhough several cardio-
vascular parameters, such as arterial pressure and LVSP measured in
vivo, are still within normal ranges. In perfused hearts, however, a
negative inotropic effect was found resulting from reduction in NKA
activity, NCX and SERCA expression and PLB increases, together with a
percentage reduction in the magnitude of the β-adrenergic response. It
is important to emphasize that, although functional changes are not
showing differences in vivo, heart function is maintained by compen-
satory or adaptive mechanisms such as sympathetic activation and
increased myosin ATPase activity. These results reinforce the relevance
of human chronic occupational exposure to small mercury concentra-
tion as a risk factor for heart function.
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